ESMO 2021: Phase 1b/2 Study of Sabizabulin (VERU-111), an Androgen Receptor Transport Disruptor, in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) Who Failed an Androgen Receptor Targeting Agent

(UroToday.com) In the Presidential Symposium 2 of the European Society for Medical Oncology (ESMO) Annual Congress focusing on prostate cancer, Dr. Mark Markowski presented data from a phase 1/2 trial of sabizabulin in men with metastatic castration resistant prostate cancer (mCRPC).